ArticleMaedica2021
Novel Aspects in Inhibiting Pancreatic Lipase with Potential New Compound from Nutmeg in Connection with Obesity -
Article in Maedica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Anti-Obesity Therapeutic Targets Studied In Silico and In Vivo: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- The Strong Inhibition of Pancreatic Lipase by Selected Indonesian Medicinal Plants as Anti-Obesity Agents.Current issues in molecular biology · 2025Review
- Therapeutic, and pharmacological prospects of nutmeg seed: A comprehensive review for novel drug potential insights.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Review
- Early Intervention ofNutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is now considered a "new world syndrome" because it is affecting developed and developing nations in all classes of people. Pancreatic lipase (PL) is the key enzyme for absorption of dietary lipids. Excessive consumption of cafeteria foods leads to obesity. Nutmeg is being used as a spice and it has many medicinal values. We aimed to see whether nutmeg could be used as a potential source of new lipase inhibitors and to explore its molecular mechanism in obesity. An in vitro study, which was performed to check its anti-lipase activity, showed a potent lipase inhibition (66.24%). A liquid chromatography-mass spectrometry (LC-MS) analysis was carried out to identify new compounds, and tetrahydrofuran (THF) with MW 536 at RT 15.2 min was isolated. A molecular docking study, that was carried out to check the interaction between THF and PL, found a PL inhibitory action of tetrahydrofuran. A further in vivo study was conducted to see PL inhibition. The percentage of fecal fat was higher in nutmeg treated rats. The size and number of adipose tissue fat cells were also decreased after treatment with nutmeg extract, which pointed to the inhibition of PL by the newly identified compound, THF. These four different types of studies suggested that nutmeg could potentially inhibit pancreatic lipase.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.